The Biopharmaceutical company is due to report FY Dec 2015 results on March 30 with a conference call to be hosted the following day. With revenue guidance of $24m issued in December 2015 we expect no surprises in terms of numbers. We look forward to updates on the plentiful clinical pipeline, of which some of the recent progress has been touched upon by news releases this year.
24 Mar 2016
Significant clinical progress to be detailed with FY2015 results
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Significant clinical progress to be detailed with FY2015 results
ProMetic Life Sciences (PLI:TSE) | 0 0 1.3% | Mkt Cap: 1,075m
- Published:
24 Mar 2016 -
Author:
Derren Nathan -
Pages:
7
The Biopharmaceutical company is due to report FY Dec 2015 results on March 30 with a conference call to be hosted the following day. With revenue guidance of $24m issued in December 2015 we expect no surprises in terms of numbers. We look forward to updates on the plentiful clinical pipeline, of which some of the recent progress has been touched upon by news releases this year.